Jaguar Health, Inc. (JAGX) stock
JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.40−0.08 (-16.67%)
Close on Nov 12, 2026Market cap $2.07MP/E –Yield –
Jaguar Health ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Jaguar Health's ebitda for the twelve months ending Jun 30, 2026 was -$23.99M. For fiscal 2025 it was -$44.00M. The highest annual figure on record is -$12.44M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$44.00M | – |
| FY2024 | Dec 31, 2024 | -$28.93M | – |
| FY2023 | Dec 31, 2023 | -$32.28M | – |
| FY2022 | Dec 31, 2022 | -$32.43M | – |
| FY2021 | Dec 31, 2021 | -$38.99M | – |
| FY2020 | Dec 31, 2020 | -$24.92M | – |
| FY2019 | Dec 31, 2019 | -$27.21M | – |
| FY2018 | Dec 31, 2018 | -$29.50M | – |
| FY2017 | Dec 31, 2017 | -$33.66M | – |
| FY2016 | Dec 31, 2016 | -$13.54M | – |
| FY2015 | Dec 31, 2015 | -$12.44M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.12M | – |
| Q1 FY2026 | Mar 31, 2026 | $10.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.79M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.33M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.39M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.15M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.02M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.22M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.39M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.30M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.19M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.34M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.78M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.18M | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.42M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.04M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.86M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.30M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.16M | – |
| Q2 FY2016 | Jun 30, 2016 | -$3.40M | – |
See a number that looks wrong?